For as long as it has had a name, Sjögren's has been treated as a dryness problem.

Dry eyes. Dry mouth. Use the drops. Drink more water. "It's mild." "It's a nuisance condition, not a serious one." "You're a working mother with teenagers, of course you're tired." "Your labs are normal." "That part is probably fibromyalgia." The same short list of answers, handed to millions of people whose bodies feel cemented every morning and whose feet burn every night — all of them built on one assumption: that if the eyes are dry and the mouth is dry, the disease lives in the eyes and the mouth, and everything else is something else.

But dry eyes don't explain the fatigue that nine hours of sleep doesn't touch. Dry mouth doesn't explain the morning stiffness, the joint pain that moves from the wrists to the hips, the burning in the feet, or the word that vanishes mid-sentence. Something has to be producing all of it. A gland problem was never really an explanation for a whole-body illness — it was the best medicine could do with an incomplete picture.

In 2026, that picture is finally starting to look more complete.

Thousands with Sjögren's are finally getting their lives back — the version of themselves they were before the diagnosis, before the drops and the lozenges and the humidifier on the nightstand — not through another prescription, not through another protocol, but through a discovery that traces back to what the body did to one specific tissue when the immune system switched on — and never switched off. It went into survival mode, it pulled supply from that tissue to fund the fight, and the change it left behind never resolved on its own — quietly producing every symptom that defines Sjögren's ever since. It was never visible on a standard test, because no standard test was ever designed to look at the tissue where it happened.

And once that finding is understood, Sjögren's stops looking like a gland problem with a dozen unrelated side effects — and starts looking like one problem, in one tissue, with a real path forward.

There is a reason every test kept coming back normal — and it is not the reason patients were given.

A Schirmer strip measures how many tears the eye produces in five minutes. A salivary flow test measures how much saliva the mouth produces in fifteen. Bloodwork looks for two antibodies — and comes back negative in nearly one in three people who have the disease. A lip biopsy takes a piece of the gland itself and counts the immune cells inside it. Every standard test a Sjögren's patient has ever been given was built to examine one thing at a time — the tears, the saliva, the blood, the gland.

None of them were built to examine the tissue the gland sits in.

Most people with Sjögren's have already been told what's wrong. That their immune system is attacking the glands that make tears and saliva. That the glands are scarring — "fibrosis." That the disease is systemic, that it goes beyond the glands, that it causes fatigue and joint pain and nerve symptoms too.

All of that is right.

What nobody told them is why. Why a gland disease produces exhaustion that nine hours of sleep doesn't touch. Why it produces a body that wakes up cemented. Why the feet burn. And why the dryness and the fatigue and the stiffness all arrived together — and never left.

The answer is a tissue called fascia — the water-rich layer of connective tissue that runs through the entire body as one continuous sheet.

Fascia wraps every muscle. It holds nearly every nerve in place. It runs alongside every blood vessel, from the scalp to the soles of the feet. In a healthy body it is soft, hydrated, and slippery, a wet cushion around everything it wraps.

Nothing is felt from it, because nothing is supposed to be. It is invisible by design. And it stays that way for one reason: the body continuously supplies it with the specific nutrients it needs to hold water.

Two things about this tissue matter more for Sjögren's than for any other condition.

First: fascia is the body's water reservoir. It is the largest water-holding tissue in the body — it holds water through a single molecule, hyaluronic acid, that binds hundreds of times its own weight in water between the tissue's layers. Which matters, because the tear glands and the saliva glands sit inside it. Glands don't make water. They draw it from the tissue around them, through vessels that run through that tissue, on a nerve signal that runs through that tissue. The gland is the tap. The fascia is the tank.

Second: over the last several years, research groups in Europe have begun examining the connective tissue of Sjögren's patients directly — not the glands, but the tissue around the tendons and the soles of the feet — and found it measurably thickened compared to healthy people. The tissue is changing body-wide. The glands are just the part that was being measured.

Which raises the question every patient asks next. What happens to that tissue when the immune system switches on and never switches off?

The answer starts with the trigger.

Most people with Sjögren's can name the season it started. A virus — mono, the flu, and since 2020, overwhelmingly COVID. A pregnancy. The years around menopause. A stretch of caregiving or grief that ran the body into the ground. Something that put the body into survival mode — the same emergency response every human body runs during a serious threat.

In Sjögren's, that emergency doesn't end. The immune system stays switched on. Researchers can measure it directly — the majority of Sjögren's patients carry a pattern in their blood called an interferon signature, the same chemical state the body runs during an active viral infection. Except there is no virus. The body is fighting, around the clock, for years.

And during survival mode, the body does something it has done for as long as there have been human bodies. To fuel the fight, it redirects its nutrient supply toward the organs it cannot afford to lose — the heart, the lungs, the brain — pulling it away from everything it can afford to run lean for a few weeks.

This is not new science. It has been an accepted, well-mapped part of human physiology for four decades. Every human body does it. Every human body is supposed to.

Fascia is one of the first places that supply gets pulled from.

For most people, this is invisible and temporary. The virus clears, the body switches out of survival mode, full supply to the fascia resumes, and nothing lasting happens.

In Sjögren's, the switch never flips back.

The immune system stays on. The body stays in survival mode. And the fascia keeps running on a fraction of what it needs — for years. Month by month, the body's water reservoir dries out. It thickens. It densifies.

And a densified reservoir does three things to the glands sitting inside it — at the same time.

The tank runs dry. The gland is still trying to draw water from the tissue around it. There is less water in that tissue to draw. So the tears thin. The saliva thins. Not because the tap broke — because the tank it draws from is empty.

The tissue closes in. As the fascia hardens, it presses on the gland and the ducts that carry what it makes. This is the "fibrosis" every Sjögren's patient has heard their rheumatologist mention — it is the tissue in and around the gland hardening. It is also why the prescription pills that force the glands to work — Salagen, Evoxac — stop working after a while. The research says so directly: once the tissue around the gland has hardened, stimulating the gland doesn't help. There is nothing left to push through.

The signal gets choked. The nerve that tells the gland to produce runs through the same tissue. Densified fascia presses on it. The instruction to make tears, to make saliva, gets physically muffled on the way to the gland.

So the eyes and the mouth aren't failing glands. They're glands sitting in a dried, hardened bed — with their supply cut off and their signal choked.

And here is the part that changes everything: the fascia doesn't stop at the glands. It is one continuous sheet. The same densified layer that is closing in on the tear glands is closing in on the muscles, the nerves, and the vessels everywhere else in the body — doing the same thing to them that it is doing to the glands.

And because fascia is wired into the nervous system, densified fascia doesn't just press. It fires. A constant stream of activation signals telling the body it's under threat — from the tissue itself. The body can't leave survival mode because the tissue keeps telling it there's an emergency — and the tissue keeps densifying because the body is locked in survival mode.

Which is why, on its own, it never resolves. Why the dryness and the fatigue and the stiffness and the burning all started at the same time. And why every symptom a Sjögren's patient lives with traces back to the same place.

For the roughly one in three people with Sjögren's who have also been handed a fibromyalgia diagnosis — often before the Sjögren's was found — this is worth sitting with. The same tissue finding is now being examined in fibromyalgia. It was never two diseases. It was one tissue, doing the same thing, given two names.

For years, Sjögren's patients have been told it's just dry eyes. Told it's mild. Told the fatigue is menopause, the stiffness is fibromyalgia, the burning is anxiety. Told their labs were normal so there was nothing to treat. Left to explain to husbands, employers, and dentists why a "dryness condition" has taken the life they had — while their doctors told them the tests were fine.

Now, for the first time, every symptom above is explained by the same finding — a single densified layer of fascia, doing the same thing everywhere in the body at once.

Not a gland problem with side effects. Not a mystery. Not something in their heads. Not something more eye drops would have fixed.

One tissue, in one state, producing everything they have been living with — and everything they have been trying to explain — for years.

Most people who have had Sjögren's for any length of time have cycled through the standard shelf.

Systane. Refresh. Restasis. Xiidra at $600 a bottle. Punctal plugs. Salagen. Evoxac and the sweating that comes with it. Biotène. Xylitol lozenges. Plaquenil. Prednisone. Methotrexate. LDN. Omega-3 by the handful. Sea buckthorn. Hyaluronic acid drops. The humidifier. And a dentist's estimate for $8,000 of crowns.

And every one of them comes with the same pattern. A small shift — twenty, thirty percent. A plateau. Then a flare, or a cold, or a dry winter, and back to where things started.

The reason is simple: every one of them is aimed at the gland, or at the immune markers.

Drops wet the surface for twenty minutes. Plugs keep what little the eye makes from draining away. Salagen and Evoxac force the gland to squeeze out whatever it has left. Plaquenil turns the immune markers down — and in the largest placebo-controlled trial ever run on it, 17.9% of patients improved on the drug and 17.2% improved on the sugar pill. Every treatment on the shelf was designed to push on the output — the tears, the saliva, the antibodies — and none of them were aimed at the tissue the gland sits in. The fascia is still densified around the glands. It is still pressing on the muscles and the nerves. It is still firing. Everything producing the symptoms is still running underneath.

It is like moisturizing the surface of a sponge that has dried out all the way through — and wondering why it's dry again by morning.

Which raised the obvious question.

If the fascia is densified — and if nothing on the standard shelf has ever been aimed at the fascia — then the real answer is not another drop, another lozenge, another prescription aimed at the gland.

The real answer is to give the fascia back the specific nutrients it stopped receiving. Enough of them, in the right forms, to rehydrate the tissue and lift the densification everything else is running on.

The problem is that the science of fascia is very new. Almost no serious research existed on this tissue until the last five years. And none of the research that did exist had ever been directed at the question that matters most — what specific nutrients does the body need to rehydrate densified fascia?

The question itself was newer than the field's ability to answer it.

That is finally changing.

In early 2025, a small group of clinicians and fascia specialists were watching the Sjögren's research come in — the interferon signature, the thickened tissue on ultrasound, the fibrosis closing in on the glands, the trial data showing the standard prescription doing nothing for the symptoms that matter — and realized something that didn't make sense.

The research had identified the tissue. The connective tissue labs had already isolated the nutrients the body uses to keep fascia hydrated — the doses, the forms. Every piece existed.

And no one had built anything with it. Millions of people with Sjögren's, a documented finding in their tissue, and not a single product on the market designed to address it — because the Sjögren's world was building eye drops and immune drugs, and the fascia researchers weren't building supplements.

So rather than wait for someone else, they decided to be first.

They founded a company called Fascial Labs, and spent the better part of a year on the formulation — sourcing the right form of each nutrient, testing doses, running iterations, working the enzymatic support required to reach the hardened tissue underneath.

What came out of it is called TrueForm® Fascial Release — the first supplement built specifically to rehydrate densified fascia.

In early 2026, Fascial Labs released the first production run of TrueForm® to an initial cohort of 1,084 adults with Sjögren's — every one of them at least two years past diagnosis, every one having already worked through the drops, the plugs, and at least one systemic prescription — and tracked their symptoms across a 90-day window.

By day 90, the numbers that came back changed how the researchers understood the finding itself.

The state the fascia is in runs in one direction.

Every flare the fascia never fully recovers from is more densification. Every layer of densification is a tighter squeeze on the glands, the nerves, and the tendon sheaths. Every tightening drops the supply further. Which produces more densification. Which produces more flares. Which produces less recovery between them.

That is what sits behind what patients describe as their baseline dropping — quietly, year over year — without anything they try interrupting it. The winter that used to mean a rough month now means a rough season. The drops that used to last an hour now last fifteen minutes. The Salagen that used to help doesn't anymore — because the tissue it was pushing against has hardened past what it can move.

And it is why "it's mild, it won't progress" so rarely holds. In long-term follow-up, the majority of people with Sjögren's develop systemic involvement over five to fifteen years — the neuropathy, the fatigue, the stiffness arriving one after another. The body doesn't stay mild in a tissue that keeps hardening. It grows into it.

The fascia today is the most responsive it will ever be. Every month it goes unaddressed, that changes.